{"id":"NCT01382225","sponsor":"Alcon Research","briefTitle":"Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome","officialTitle":"A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2011-06-27","resultsPosted":"2013-07-08","lastUpdate":"2013-07-08"},"enrollment":1936,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DRUG","name":"Sodium Hyaluronate Ophthalmic Solution, 0.18%","otherNames":[]},{"type":"OTHER","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Sodium Hyaluronate","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.","primaryOutcome":{"measure":"Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7","timeFrame":"Baseline, Day 7","effectByArm":[{"arm":"Sodium Hyaluronate","deltaMin":4.9,"sd":2.2},{"arm":"Vehicle","deltaMin":4.8,"sd":2.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":723},"commonTop":[]}}